Wockhardt Ltd
Wockhardt Q3 FY22 earnings call: Revenue & Margins
Q3 FY22 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #17 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Wockhardt Ltd's Q3 FY22 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Net Sales Revenues for 9M FY22: INR 2,575 Cr (Page 4) - Profit After Tax (9M FY22): INR 32 Cr (Page 4) - EBITDA (9M FY22): INR 331 Cr (Page 4) - Year-on-year growth mentioned as 24% (Page 4) - Net Debt-Equity Ratio improved to 0.34x (Page 5) - International business contributes >80% of revenue (Page 4) - EBITDA (9M FY22): INR 331 Cr, showing 24% year-on-year growth (Page 4) - Profit After Tax (PAT) (9M FY22): INR 32 Cr, improved from -138 Cr (FY20-21) and -296 Cr (FY19-20) (Page 4)
From Wockhardt Ltd's Q3 FY22 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Net Sales Revenues for 9M FY22: INR 2,575 Cr (Page 4)
- Profit After Tax (9M FY22): INR 32 Cr (Page 4)
- EBITDA (9M FY22): INR 331 Cr (Page 4)
- Year-on-year growth mentioned as 24% (Page 4)
2 more points from Wockhardt Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Wockhardt Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- It highlights manufacturing capacity readiness for diabetes biosimilars (insulin & GLP-1 analogs) for US, Europe, and emerging markets.
- Mentions global CMO supply for COVID-19 vaccines, with existing India & UK sites providing flexibility and >100 million doses supplied.
- The business has 12 manufacturing facilities globally and integrated end-to-end capabilities from development to marketing.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Wockhardt Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Wockhardt Ltd said on order book & pipeline — free account, 30 seconds.
Wockhardt Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹969 Cr, net profit ₹73 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Wockhardt's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q3 FY24 earnings call analysis →
Earlier calls (1)
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Wockhardt Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Wockhardt Ltd Q3 FY22 results?
Net Sales Revenues for 9M FY22: INR 2,575 Cr (Page 4) - Profit After Tax (9M FY22): INR 32 Cr (Page 4) - EBITDA (9M FY22): INR 331 Cr (Page 4) - Year-on-year growth mentioned as 24% (Page 4) - Net Debt-Equity Ratio improved to 0.34x (Page 5) - International business contributes >80% of revenue (Page 4) - EBITDA (9M FY22): INR 331 Cr, showing 24% year-on-year growth (Page 4) - Profit After Tax (PAT) (9M FY22): INR 32 Cr, improved from -138 Cr (FY20-21) and -296 Cr (FY19-20) (Page 4)
What is Wockhardt Ltd share price analysis?
Wockhardt Ltd currently shows a neutral. The stock trades at a P/E of 85.0 with a market cap of ₹33,897 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Wockhardt Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.